Natural Capsules Limited has expanded the agenda for its upcoming Board of Directors meeting on August 12, 2026, to include a significant capital-raising initiative. In addition to approving the unaudited consolidated and standalone financial results for the quarter ended June 30, 2026 (Q1FY26), the Board will evaluate a proposal to raise funds through the preferential issue of equity shares, convertibles, or other eligible securities. This move signals the company’s intent to strengthen its capital base, subject to necessary regulatory and shareholder approvals.

The company notified the Bombay Stock Exchange (BSE) and the National Stock Exchange of India Limited (NSE) on August 9, 2026, regarding this addition to the agenda previously intimated on August 4, 2026. The proposed fund raising is contingent upon obtaining all required regulatory and statutory approvals, as well as explicit approval from the company’s shareholders. The specific amount to be raised or the target investors have not been disclosed in this filing.

Regulatory Compliance and Trading Window

In adherence to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company’s internal Code of Conduct for the Prevention of Insider Trading, the trading window for dealing in the equity shares of Natural Capsules Limited remains closed. This restriction applies to all Designated Persons and their immediate relatives. The window will remain shut from July 1, 2026, until 48 hours after the declaration of the financial results for the quarter ended June 30, 2026.

Key Agenda Items

The Board meeting on August 12, 2026, focuses on two primary areas:

Akshay Dutta, Company Secretary and Compliance Officer of Natural Capsules Limited, signed the communication to the exchanges. The filing underscores the procedural steps required before any capital infusion can proceed, highlighting the need for shareholder consent alongside regulatory clearances.

Natural Capsules Limited's material unlisted subsidiary, Natural Biogenex Private Limited , has completed the allotment of its recent rights issue, issuing 9,46,305 equity shares of ₹10 each for cash at par. The transaction raises ₹94.63 lakh and formally concludes a process that diluted the parent company's stake by 2.18%, reducing its holding from 68.96% to 66.78%. This development confirms the capital structure changes previously disclosed following Natural Capsules' decision not to subscribe to the issue.

The Board of Directors of Natural Biogenex approved the allotment on July 31, 2026, acting on earlier authorization granted during a board meeting on July 10, 2026. The rights issue subscription period had run from July 14, 2026, to July 28, 2026. Natural Capsules Limited opted out of subscribing to the new shares, leading to the dilution of its equity interest while retaining control over the subsidiary. The company notified both the Bombay Stock Exchange and the National Stock Exchange under Regulation 30(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Allotment Details

The finalized allotment involves the issuance of 9,46,305 equity shares with a face value of ₹10 each. The total consideration received amounts to ₹94,63,050. These shares were allotted to third-party applicants who exercised their rights during the subscription window. Akshay Dutta, Company Secretary and Compliance Officer of Natural Capsules Limited, signed the disclosure dated July 31, 2026, from Bangalore.

Impact on Shareholding

Prior to the rights issue, Natural Capsules Limited held 1,99,99,996 equity shares, representing 68.96% of the paid-up capital of Natural Biogenex. The absolute number of shares held by the parent company remains unchanged at 1,99,99,996. However, the issuance of new shares to third parties has reduced the percentage holding to 66.78% of the revised paid-up capital. Despite this dilution, Natural Biogenex remains a controlled subsidiary, meaning Natural Capsules retains authority over its operations and financial policies.

Financial Context

The rights issue occurs against a backdrop of significant financial stress at Natural Biogenex Private Limited. For the last financial year, the subsidiary reported a turnover of ₹13.43 crore but incurred a substantial loss of ₹43.30 crore. Despite these operational losses, the subsidiary maintains a net worth of ₹81.24 crore. The parent company's decision to avoid further capital infusion into the loss-making unit suggests a focus on preserving cash for core operations or higher-return opportunities elsewhere. The transaction is not classified as a related party transaction, as the dilution resulted from allotment to third parties rather than a transfer between related entities.